Pharmacovigilance in hospice/palliative care: Net effect of amitriptyline or nortriptyline on neuropathic pain: UTS/IMPACCT Rapid programme international consecutive cohort.
Cohort study
amitriptyline
neuropathic pain
nortriptyline
pharmacovigilance
post-marketing surveillance
Journal
Palliative medicine
ISSN: 1477-030X
Titre abrégé: Palliat Med
Pays: England
ID NLM: 8704926
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
12
4
2022
medline:
9
6
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Real-world effectiveness of interventions in palliative care need to be systematically quantified to inform patient/clinical decisions. Neuropathic pain is prevalent and difficult to palliate. Tricyclic antidepressants have an established role for some neuropathic pain aetiologies, but this is less clear in palliative care. To describe the real-world use and outcomes from amitriptyline An international, prospective, consecutive cohort post-marketing/phase IV/pharmacovigilance/quality improvement study of palliative care patients with neuropathic pain where the treating clinician had already made the decision to use a tricyclic antidepressant. Data were entered at set times: baseline, and days 7 and 14. Likert scales graded benefits and harms. Twenty-one sites (inpatient, outpatient, community) participated in six countries between June 2016 and March 2019. Patients had clinician-diagnosed neuropathic pain. One hundred and fifty patients were prescribed amitriptyline (110) Benefits favoured amitriptyline while harms were similar for both medications.
Sections du résumé
BACKGROUND
Real-world effectiveness of interventions in palliative care need to be systematically quantified to inform patient/clinical decisions. Neuropathic pain is prevalent and difficult to palliate. Tricyclic antidepressants have an established role for some neuropathic pain aetiologies, but this is less clear in palliative care.
AIM
To describe the real-world use and outcomes from amitriptyline
DESIGN
An international, prospective, consecutive cohort post-marketing/phase IV/pharmacovigilance/quality improvement study of palliative care patients with neuropathic pain where the treating clinician had already made the decision to use a tricyclic antidepressant. Data were entered at set times: baseline, and days 7 and 14. Likert scales graded benefits and harms.
SETTING/PARTICIPANTS
Twenty-one sites (inpatient, outpatient, community) participated in six countries between June 2016 and March 2019. Patients had clinician-diagnosed neuropathic pain.
RESULTS
One hundred and fifty patients were prescribed amitriptyline (110)
CONCLUSIONS
Benefits favoured amitriptyline while harms were similar for both medications.
Identifiants
pubmed: 35403513
doi: 10.1177/02692163221085855
doi:
Substances chimiques
Antidepressive Agents, Tricyclic
0
Amitriptyline
1806D8D52K
Nortriptyline
BL03SY4LXB
Types de publication
Clinical Trial, Phase IV
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM